Enantioselective syntheses of aeruginosin 298-A and its analogues using a catalytic asymmetric phase-transfer reaction and epoxidation

Journal of the American Chemical Society

Volumn 125, Issue 37, 2003, Pages 11206-11207

  Ohshima, Takashi ^a   Gnanadesikan, Vijay ^a   Shibuguchi, Tomoyuki ^a   Fukuta, Yuhei ^a   Nemoto, Tetsuhiro ^a   Shibasaki, Masakatsu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AERUGINOSIN 298 A; CINCHONA ALKALOID; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DIASTEREOISOMER; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOSELECTIVITY; EPOXIDATION; STRUCTURE ACTIVITY RELATION;

CATALYSIS; EPOXY COMPOUNDS; LEUCINE; MOLECULAR STRUCTURE;

EID: 0043194288     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja037290e     Document Type: Article

References (23)

1. Vacca, J. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: San Diego, 1998; Vol. 33, p 81.
2. (a) Murakami, M.; Okita, Y.; Matsuda, H.; Okino, T.; Yamaguchi, K. Tetrahedron Lett. 1994, 35, 3129.
3. (b) Matsuda, H.; Okino, T.; Murakami, M.; Yamaguchi, K. Tetrahedron 1996, 52, 14501.
4. (a) Valls, N.; López-Canet, M.; Vallribera, M.; Bonjoch, J. J. Am. Chem. Soc. 2000, 122, 11248.
5. (b) Valls, N.; López-Canet, M.; Vallribera, M.; Bonjoch, J. Chem.-Eur. J. 2001, 7, 3446.
6. Wipf, P.; Mthot, J.-L. Org. Lett. 2000, 2, 4213.
7. For a recent review, see: Maruoka, K.; Ooi, T. Chem. Rev. 2003, 103, 3013.
8. For representative examples, see: (a) O'Donnell, M. J.; Bennett, W. D.; Wu, S. J. Am. Chem. Soc. 1989, 111, 2353.
9. (b) Corey, E. J.; Xu, F.; Noe, M. C. J. Am. Chem. Soc. 1997, 119, 12414.
10. (c) Lygo, B.; Wainwright, P. G. Tetrahedron Lett. 1997, 38, 8595.
11. (d) Park, H.-g.; Jeong, B.-S.; Yoo, M.-S.; Lee, J.-H.; Park, M.-k.; Lee, Y.-J.; Kim, M.-J.; Jew, S.-s. Angew. Chem., Int. Ed. 2002, 41, 3036.
12. For representative examples, see: (a) Ooi, T.; Kaneda, M.; Maruoka, K. J. Am. Chem. Soc. 1999, 121, 6519.
13. (b) Belokon, Y. N.; Kochetkov, K. A.; Churkina, T. D.; Ikonnikov, N. S.; Larionov, O. V.; Harutyunyan, S. R.; Vyskocil, S.; North, M.; Kagan, H. B. Angew. Chem., Int. Ed. 2001, 40, 1948.
14. (c) Kita, T.; Georgieva, A.; Hashimoto, Y.; Nakata, T.; Nagasawa, K. Angew. Chem., Int. Ed. 2002, 41, 2832.
15. (d) Arai, S.; Tsuji, R.; Nishida, A. Tetrahedron Lett. 2002, 43, 9535.
16. (e) Mase, N.; Ohno, T.; Hoshikawa, N.; Ohishi, K.; Morimoto, H.; Yoda, H.; Takabe, K. Tetrahedron Lett. 2003, 44, 4073.
17. Shibuguchi, T.; Fukuta, Y.; Akachi, Y.; Sekine, A.; Ohshima, T.; Shibasaki, M. Tetrahedron Lett. 2002, 43, 9539.
18. For details, see Supporting Information.
19. Optically pure compound was obtained by recrystallization. See Supporting Information.
20. Nemoto, T.; Kakei, H.; Gnanadesikan, V.; Tosaki, S.-y.; Ohshima, T.; Shibasaki, M. J. Am. Chem. Soc. 2002, 124, 14544.
21. 3P=O. see: Daikai, M.; Kamaura, M.; Inanaga, J. Tetrahedron Lett. 1998, 39, 7321 and ref 11.
22. 3 = CHO), the other alcohols were protected with TIPS, although this is not necessary for the synthesis of 1a.
23. 13C NMR spectra were identical to the reported data after treatment with TFA in EtOH.